www.financialexpress.com

www.financialexpress.com
Share

The US health regulator has cleared Glenmark Pharma’s investigational new drug application to initiate phase one study of GBR 1342, a humanised monoclonal antibody for the treatment of multiple myeloma, the company said today. This is Glenmark’s second investigational new drug from its immuno-oncology portfolio to enter clinical trials. “GBR 1342...

India’s largest pharmaceutical firms are looking to convince US President Donald Trump that his promise to lower drug costs should take priority over his vow to make sure the medicines are made in America. Savings from cheaper imported drugs will outweigh the jobs created by producing them in the US, the Indian Pharmaceutical Alliance, which...

www.financialexpress.com

 •  February 14

US President Barack Obama’s recent visit to India has brought the focus back on data protection (DP) and patent linkage (PL) — two areas where Washington, at the behest of Big Pharma, has for several years been nudging the government here, albeit with little success. With the government’s change of stance, according to sources, the PMO and the...

www.financialexpress.com

 •  February 14

As investors raised concerns on dwindling sales and slowing growth at Dr Reddy Laboratories, India’s second-biggest drug maker by sales, the company has now charted a four-pronged strategy aimed at reviving dwindling sales and improving profitability. The Hyderabad-based company plans to expand into more countries, especially in Europe; invest in...

www.financialexpress.com

 •  February 14

Even as Washington deliberates imposing trade sanctions on India, a move that could impact import of pharmaceutical, gems & jewellery and petroleum products into the US, Indias intellectual property (IP) regime and patent laws have got strong support from US-based law professors and non-profit organisations as well as leading MNCs such as Boeing...

www.financialexpress.com

 •  February 14

In a big relief to drug companies, the Narendra Modi government has thwarted a controversial move by a regulator to extend price controls to larger segments of the Indian pharmaceutical market by citing public interest and prevalence of extraordinary circumstances. Following an order by the department of pharmaceuticals in the ministry of chemicals...